Koushyar S. et al, 2017. The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis (2017) 6, e333; doi:10.1038/oncsis.2017.32
The authors are working to better understand the development of androgen resistant prostate cancer, specifically the role of the androgen receptor corepressor, prohibitin (PHB), which is often downregulated by androgen treatment. The authors identify PHB-mediated repression of genes essential for DNA replication and synthesis, (e.g. MCMs and TK1), via an E2F1 regulated pathway and further study the role of direct interaction between the PHB and E2F1 proteins using several methods: co-immunoprecipitation from prostate cancer nuclear extracts, Checkmate mammalian two-hybrid assay and a NanoBiT PPI assay that they developed. The authors performed the NanoBiT protein interaction assay (LgBiT-PHB, SmBiT-E2F1) in both COS-7 and LNCaP cells so that the interaction could be monitored in real-time in the presence of absence of androgen treatment and demonstrated low constitutive interaction which was inhibited by androgen treatment.
The article can be found here: http://www.nature.com/oncsis/journal/v6/n5/full/oncsis201732a.html?WT.feed_name=subjects_cancer